Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

BACKGROUND: Irinotecan is approved and widely administered to metastatic colorectal cancer (mCRC) patients; however, it can cause severe toxicities including neutropenia and diarrhea. The polymorphisms of genes encoding drug-metabolizing enzymes can play a crucial role in the increased susceptibilit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Trials
Autores principales: Yeh, Yung-Sung, Tsai, Hsiang-Lin, Huang, Ching-Wen, Wang, Jui-Ho, Lin, Yi-Wen, Tang, Hsiu-Chih, Sung, Yung-Chuan, Wu, Chang-Chieh, Lu, Chien-Yu, Wang, Jaw-Yuan
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4727397/
https://ncbi.nlm.nih.gov/pubmed/26811156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-016-1153-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares